Rhonda Farnum Sells 13,314 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the sale, the senior vice president owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This trade represents a 5.42% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH traded up $0.02 during mid-day trading on Wednesday, hitting $16.71. The stock had a trading volume of 386,153 shares, compared to its average volume of 348,652. The company has a market cap of $861.40 million, a PE ratio of 7.60 and a beta of 0.17. Theravance Biopharma, Inc. has a 12-month low of $10.44 and a 12-month high of $21.03. The company’s 50 day moving average is $16.49 and its 200-day moving average is $17.40.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, equities research analysts predict that Theravance Biopharma, Inc. will post 1.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in Theravance Biopharma in the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd lifted its position in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Analysts Set New Price Targets

TBPH has been the subject of several research analyst reports. B. Riley Financial upped their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Tuesday, April 7th. Oppenheimer downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Weiss Ratings downgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $21.40.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.